Addex Therapeutics Ltd (ADXN)

NASDAQ: ADXN · IEX Real-Time Price · USD
5.78
+0.23 (4.14%)
At close: Dec 1, 2023, 4:00 PM
5.94
+0.16 (2.77%)
After-hours: Dec 1, 2023, 4:46 PM EST
4.14%
Market Cap 6.08M
Revenue (ttm) 2.24M
Net Income (ttm) -12.34M
Shares Out 1.05M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,056
Open 5.80
Previous Close 5.55
Day's Range 5.52 - 6.02
52-Week Range 5.10 - 45.60
Beta 1.75
Analysts n/a
Price Target n/a
Earnings Date Nov 29, 2023

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 24
Stock Exchange NASDAQ
Ticker Symbol ADXN
Full Company Profile

Financial Performance

In 2022, ADXN's revenue was 1.44 million, a decrease of -54.18% compared to the previous year's 3.15 million. Losses were -20.80 million, 35.5% more than in 2021.

Financial numbers in CHF Financial Statements

News

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 mGlu2 NAM cognition program receives a €4 million Eurostars grant CHF 4.8M ($5.2M)...

4 days ago - GlobeNewsWire

Addex Convenes Extraordinary General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modul...

5 days ago - GlobeNewsWire

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...

10 days ago - GlobeNewsWire

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical comp...

19 days ago - GlobeNewsWire

Addex Regains Nasdaq Listing Compliance

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-b...

25 days ago - GlobeNewsWire

Addex Announces Participation in the Bio-Europe 2023 Conference

Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...

4 weeks ago - GlobeNewsWire

Addex Completes ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-b...

6 weeks ago - GlobeNewsWire

Addex Announces Plan to Implement ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-ba...

2 months ago - GlobeNewsWire

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Addex led consortium wins Eurostar s grant to deliver clinical candidates to treat mild neurocognitive disorder s Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 202 3 - ...

2 months ago - GlobeNewsWire

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, tod...

3 months ago - GlobeNewsWire

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Cohort 1 is completed , and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...

3 months ago - GlobeNewsWire

Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions First time mGlu5 linked to post - stroke functional recovery Ad Hoc Announcement Pursuant ...

3 months ago - GlobeNewsWire

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

ADX71149 Phase 2 e pilepsy c linical s tudy Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendation Indivior GABAB PAM collaboration extended to June 2024...

4 months ago - GlobeNewsWire

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Geneva, Switzerland, August 3 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today a...

4 months ago - GlobeNewsWire

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration

Discovery c ollaboration on track to deliver clinical candidate s for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3 , 202 3 - Addex Therapeutics...

4 months ago - GlobeNewsWire

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Data published in Neuropharmacology shows mGlu2 PAM s attenuate oxycodone use and potential as a novel treatment f or opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland...

4 months ago - GlobeNewsWire

Addex Increases Issued Share Capital to Create Treasury Shares

Ad Hoc Announcement Pursuant to Art.   53 LR   Geneva, Switzerland, June 1 5 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mo...

6 months ago - GlobeNewsWire

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art.   53 LR   Geneva, Switzerland, June 1 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu...

6 months ago - GlobeNewsWire

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Ad Hoc Announcement Pursuant to Art.   53 LR   Geneva, Switzerland, May 1 8 , 202 2 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mod...

7 months ago - GlobeNewsWire

Addex Reports Q1 2023 Financial Results and Provides Corporate Update

ADX71149 Phase 2 e pilepsy c linical s tudy's i ndependent i nterim r eview c ommittee (“IRC”) r ecommends c ontinuing s tudy  CHF 5.6M ($ 6.1 M) of cash and cash equivalents at March 31, 202 3 Ad Hoc...

7 months ago - GlobeNewsWire

Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing Study

Cohort 1 progressing through P art 2 Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical...

7 months ago - GlobeNewsWire

Addex Convenes Annual General Meeting 2023

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-...

7 months ago - GlobeNewsWire

Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

Geneva, Switzerland, May 4 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today anno...

7 months ago - GlobeNewsWire

Addex Completes $5.0 Million Equity Financing

Proceeds to advance allosteric modulator therapeutic pipeline

8 months ago - GlobeNewsWire